IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study

BACKGROUND: IBI362 (LY3305677) is a novel weekly-dose glucagon-like peptide-1 and glucagon receptor dual agonist being developed for the treatment of obesity and type 2 diabetes. The aim of this randomised, placebo-controlled, multiple ascending dose phase 1b study was to evaluate the safety, tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Linong, Jiang, Hongwei, An, Pei, Deng, Huan, Liu, Meng, Li, Li, Feng, Liqi, Song, Baili, Han-Zhang, Han, Ma, Qingyang, Qian, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374649/
https://www.ncbi.nlm.nih.gov/pubmed/34430840
http://dx.doi.org/10.1016/j.eclinm.2021.101088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374649/
https://www.ncbi.nlm.nih.gov/pubmed/34430840
http://dx.doi.org/10.1016/j.eclinm.2021.101088

Ejemplares similares